Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$16.99 USD
+0.24 (1.43%)
Updated Jul 16, 2024 04:00 PM ET
5-Strong Sell of 5 5
C Value A Growth A Momentum A VGM
Brokerage Reports
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 41 - 60 ( 424 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q23 Recap - Upside Likely, But Duration Questions
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sights on Firdapse Label Expansion, Fycompa Near-Term Growth; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse and Fycompa Dual Commercial Reach to Establish 2023 Growth; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q22 Recap - Trends Strong; Fycompa Boosting #''s
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Right Place, Unexpected Timing-Reconciling Announced ANDA and Separate FDA Orphan Drug Exclusivity Position
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Opening Presents Early-Epilepsy Asset and Upside Added to Platform, PT Up to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department